Erudio Healtherudio.com
Sponsor
Dana-Farber Cancer Institute trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by Dana-Farber Cancer Institute: PROMISE. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 24 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Dana-Farber Cancer Institute). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| PROMISE NCT03689595 · Dana-Farber Cancer Institute | high-risk population screened for multiple myeloma | Observational | 585 | 105 | Deep | Nov 2, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| NCT00542451 NCT00542451 · Dana-Farber Cancer Institute DeepView → | node-negative HER2-positive breast cancer | Phase 2 | Deep | View | |||
| FORMULA-509 NCT03141671 · Dana-Farber Cancer Institute DeepView → | prostate cancer with rising PSA after radical prostatectomy | Phase 2 | Deep | View | |||
| CAR-PRISM NCT05767359 · Dana-Farber Cancer Institute DeepView → | high-risk smoldering multiple myeloma | Phase 2 | Deep | View | |||
| DAD-IO NCT04724018 · Dana-Farber Cancer Institute DeepView → | metastatic urothelial carcinoma | Phase 1/Phase 2 | Deep | View | |||
| NIMBUS NCT03789110 · Dana-Farber Cancer Institute DeepView → | hypermutated HER2-negative metastatic breast cancer | Phase 2 | Deep | View | |||
| STOP-HER2 NCT05721248 · Dana-Farber Cancer Institute DeepView → | HER2-positive metastatic breast cancer | Phase 2 | Deep | View | |||
| ATEMPT 2.0 NCT04893109 · Dana-Farber Cancer Institute DeepView → | stage I HER2-positive breast cancer | Phase 2 | Deep | View | |||
| SAPPHO NCT06439693 · Dana-Farber Cancer Institute StandardView → | de novo HER2+ metastatic breast cancer | Phase 2 | Standard | View | |||
| Saci-IO TNBC NCT04468061 · Dana-Farber Cancer Institute StandardView → | PD-L1-negative metastatic triple-negative breast cancer | Phase 2 | Standard | View | |||
| ASPRIA NCT04434040 · Dana-Farber Cancer Institute FocusedView → | triple-negative breast cancer with residual cancer | Phase 2 | Focused | View | |||
| NCT01942837 NCT01942837 · Dana-Farber Cancer Institute FocusedView → | metastatic castration-resistant prostate cancer | Phase 2 | Focused | View | |||
| NCT02025010 NCT02025010 · Dana-Farber Cancer Institute FocusedView → | castration-resistant prostate cancer | Phase 2 | Focused | View | |||
| I-PRISM NCT02916771 · Dana-Farber Cancer Institute FocusedView → | high-risk smoldering multiple myeloma | Phase 2 | Focused | View | |||
| NCT03113643 NCT03113643 · Dana-Farber Cancer Institute FocusedView → | Not given | Phase 1 | Focused | View | |||
| NCT03485547 NCT03485547 · Dana-Farber Cancer Institute FocusedView → | Not given | Phase 1 | Focused | View | |||
| LuCarbo NCT06303713 · Dana-Farber Cancer Institute FocusedView → | metastatic castration-resistant prostate cancer | Phase 1 | Focused | View | |||
| NCT03534323 NCT03534323 · Dana-Farber Cancer Institute FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| YCT NCT05121558 · Dana-Farber Cancer Institute FocusedView → | chemotherapy-induced peripheral neuropathy | Not applicable | Focused | View | |||
| NCT01614821 NCT01614821 · Dana-Farber Cancer Institute FocusedView → | Not given | Phase 2 | Focused | View | |||
| NCT02362997 NCT02362997 · Dana-Farber Cancer Institute FocusedView → | relapsed/refractory classical Hodgkin lymphoma, DLBCL or PTCL | Phase 2 | Focused | View | |||
| NCT02677324 NCT02677324 · Dana-Farber Cancer Institute FocusedView → | Not given | Phase 2 | Focused | View | |||
| PELOPS NCT02764541 · Dana-Farber Cancer Institute FocusedView → | early invasive lobular or ductal breast cancer | Phase 2 | Focused | View | |||
| QUILT-505 NCT06239220 · Dana-Farber Cancer Institute FocusedView → | immunotherapy-treated recurrent metastatic HNSCC | Phase 2 | Focused | View | |||
| NCT06318871 NCT06318871 · Dana-Farber Cancer Institute FocusedView → | Not given | Early phase 1 | Focused | View | |||